Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Bezprozvanny I, Klockgether T.

Drugs Future. 2009 Dec;34(12). doi: 10.1358/dof.2009.034.12.1443434.

2.
3.

Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Chen X, Wu J, Luo Y, Liang X, Supnet C, Kim MW, Lotz GP, Yang G, Muchowski PJ, Kodadek T, Bezprozvanny I.

Chem Biol. 2011 Sep 23;18(9):1113-25. doi: 10.1016/j.chembiol.2011.06.010.

4.

Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.

Wu J, Shih HP, Vigont V, Hrdlicka L, Diggins L, Singh C, Mahoney M, Chesworth R, Shapiro G, Zimina O, Chen X, Wu Q, Glushankova L, Ahlijanian M, Koenig G, Mozhayeva GN, Kaznacheyeva E, Bezprozvanny I.

Chem Biol. 2011 Jun 24;18(6):777-93. doi: 10.1016/j.chembiol.2011.04.012.

5.

Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.

Bezprozvanny I.

Neurochem Res. 2011 Jul;36(7):1186-97. doi: 10.1007/s11064-010-0393-y. Review.

6.

The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.

Inan S, Wei H.

Anesth Analg. 2010 Dec;111(6):1400-10. doi: 10.1213/ANE.0b013e3181f7181c. Review.

PMID:
20861418
7.

Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease.

Milnerwood AJ, Raymond LA.

Trends Neurosci. 2010 Nov;33(11):513-23. doi: 10.1016/j.tins.2010.08.002. Review.

PMID:
20850189
8.

Role of presenilins in neuronal calcium homeostasis.

Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I.

J Neurosci. 2010 Jun 23;30(25):8566-80. doi: 10.1523/JNEUROSCI.1554-10.2010.

9.

Deranged calcium signaling in Purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias.

Kasumu A, Bezprozvanny I.

Cerebellum. 2012 Sep;11(3):630-9. doi: 10.1007/s12311-010-0182-9. Review.

10.

Tetrabenazine is neuroprotective in Huntington's disease mice.

Wang H, Chen X, Li Y, Tang TS, Bezprozvanny I.

Mol Neurodegener. 2010 Apr 26;5:18. doi: 10.1186/1750-1326-5-18.

11.

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin.

Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA.

Nat Med. 2009 Dec;15(12):1407-13. doi: 10.1038/nm.2056.

12.

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.

Bauer PO, Nukina N.

J Neurochem. 2009 Sep;110(6):1737-65. doi: 10.1111/j.1471-4159.2009.06302.x. Review.

13.

Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.

Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I.

J Neurosci. 2009 Jul 22;29(29):9148-62. doi: 10.1523/JNEUROSCI.0660-09.2009.

14.

Calcium signaling and neurodegenerative diseases.

Bezprozvanny I.

Trends Mol Med. 2009 Mar;15(3):89-100. doi: 10.1016/j.molmed.2009.01.001.

15.

Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.

Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I.

J Neurosci. 2009 Feb 4;29(5):1257-66. doi: 10.1523/JNEUROSCI.4411-08.2009.

16.

Ginsenosides protect striatal neurons in a cellular model of Huntington's disease.

Wu J, Jeong HK, Bulin SE, Kwon SW, Park JH, Bezprozvanny I.

J Neurosci Res. 2009 Jun;87(8):1904-12. doi: 10.1002/jnr.22017.

17.

Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3.

Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I.

J Neurosci. 2008 Nov 26;28(48):12713-24. doi: 10.1523/JNEUROSCI.3909-08.2008.

18.

Evaluation of Dimebon in cellular model of Huntington's disease.

Wu J, Li Q, Bezprozvanny I.

Mol Neurodegener. 2008 Oct 21;3:15. doi: 10.1186/1750-1326-3-15.

19.

Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Muehlschlegel S, Sims JR.

Neurocrit Care. 2009;10(1):103-15. doi: 10.1007/s12028-008-9133-4. Review.

20.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010.

Items per page

Supplemental Content

Support Center